GTS Securities LLC Decreases Stake in argenx SE (NASDAQ:ARGX)

GTS Securities LLC cut its stake in shares of argenx SE (NASDAQ:ARGX - Free Report) by 75.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 501 shares of the company's stock after selling 1,531 shares during the quarter. GTS Securities LLC's holdings in argenx were worth $308,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. GeoWealth Management LLC increased its stake in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares in the last quarter. Whipplewood Advisors LLC acquired a new stake in argenx in the fourth quarter valued at $37,000. Global Retirement Partners LLC increased its position in shares of argenx by 369.2% in the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after buying an additional 48 shares in the last quarter. FIL Ltd acquired a new position in shares of argenx during the 4th quarter worth $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of argenx during the 4th quarter worth $38,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenx Stock Up 2.0%

Shares of ARGX traded up $11.34 during mid-day trading on Monday, hitting $584.60. The company had a trading volume of 275,914 shares, compared to its average volume of 323,285. argenx SE has a 1-year low of $368.57 and a 1-year high of $678.21. The business's 50-day simple moving average is $586.59 and its 200-day simple moving average is $612.78. The stock has a market cap of $35.70 billion, a PE ratio of -664.32 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, sell-side analysts expect that argenx SE will post 3.13 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ARGX shares. William Blair reissued an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Robert W. Baird raised shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price objective for the company in a research note on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft upgraded argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Finally, Oppenheimer boosted their price target on argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. One analyst has rated the stock with a hold rating, nineteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $709.18.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.